Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
Public ClinicalTrials.gov record NCT00310375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.
Study identification
- NCT ID
- NCT00310375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2006 (Actual)
- Primary completion
- Nov 30, 2016 (Actual)
- Completion
- Mar 15, 2017 (Actual)
- Last update posted
- Jul 31, 2020
2006 – 2017
United States locations
- U.S. sites
- 30
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama -- Department of Neurology/Epilepsy Center | Birmingham | Alabama | 35294 | — |
| North Alabama Neuroscience Research Associates | Huntsville | Alabama | 35801 | — |
| Neurology Clinic | Northport | Alabama | 35476 | — |
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Clinical Trials Inc. | Little Rock | Arkansas | 72205 | — |
| UCSD Thornton Hospital | La Jolla | California | 92037 | — |
| University of Southern California -- Keck School of Medicine | Los Angeles | California | 90033 | — |
| West Los Angeles VA Healthcare Center | Los Angeles | California | 90073 | — |
| Delta Waves | Colorado Springs | Colorado | 80918 | — |
| University of Colorado Department Of Neurology | Denver | Colorado | 80010 | — |
| University of Florida -- Shands Jacksonville | Jacksonville | Florida | 32209 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Lovelace Scientific Resources | Sarasota | Florida | 34233 | — |
| McFarland Clinic | Ames | Iowa | 50010 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda | Maryland | 20817 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Minnesota Epilepsy Group, P.A. | Saint Paul | Minnesota | 55102 | — |
| The Comprehensive Epilepsy Care Center for Children and Adults | Chesterfield | Missouri | 63017 | — |
| Beth Israel Medical Center | New York | New York | 10003 | — |
| Asheville Neurology Specialists | Asheville | North Carolina | 28801 | — |
| Medical University of Ohio at Toledo | Toledo | Ohio | 43614 | — |
| Oregon Neurology PC | Tualatin | Oregon | 97062 | — |
| Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37212 | — |
| Medical City Dallas Hospital | Dallas | Texas | 75230 | — |
| Neurological Clinic of Texas | Dallas | Texas | 75230 | — |
| Memorial Hermann Hospital | Houston | Texas | 77030 | — |
| University of Virginia Comprehensive Epilepsy Program | Charlottesville | Virginia | 22903 | — |
| Virginia Commonwealth University Medical Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00310375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00310375 live on ClinicalTrials.gov.